Peeling Back The Layers: Exploring Becton Dickinson Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Analysts have recently provided mixed reviews on Becton Dickinson (NYSE:BDX), with 4 somewhat bullish ratings in the past three months. The average 12-month price target has been lowered to $276.00 from $297.00, indicating a 7.07% decrease. Analysts from Raymond James and Piper Sandler have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Becton Dickinson is a major medical surgical products manufacturer, with BD Medical, BD Life Sciences, and BD Interventional as its business segments. The company's financials show solid revenue growth but below-average profitability and efficiency metrics.
January 03, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Becton Dickinson has received somewhat bullish ratings from analysts, but the average price target has been reduced, indicating potential pressure on the stock price in the short term.
The reduction in the average price target by analysts suggests that there may be concerns about the company's future performance, which could lead to a negative impact on the stock price in the short term. The somewhat bullish ratings indicate that analysts see potential in the company, but the lowered targets and below-average profitability and efficiency metrics could temper investor enthusiasm.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100